ClinicalTrials.gg
Enrolling by invitationNCT07831525CURRENT-FlowUpdated Sep 21, 2026

Effect of Different Currents for Transcranial Modulation of the Sensorimotor Corticospinal Pathway in Healthy Subjects

An interventional study of Transcranial Alternating Current Stimulation and Transcranial Direct Current Stimulation in Health Adult Subjects, sponsored by Hospital de Clinicas de Porto Alegre. Enrolling by invitation at 1 site in Brazil. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Hospital de Clinicas de Porto Alegre · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Transcranial modulation of the corticospinal sensorimotor pathway is a promising approach in neuroscientic functions. Among the techniques used, transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS) and the application of random noise current stand out. Objective: To compare the e stimulus, in the EEG frequency bands, on Motor Evoked Potentials (MEP) and on the functional activation of the motor cortex, assessed by Functional Near Infrared Spectroscopy (fNIRS) and pain measurements in healthy subjects subjected to a standardized algogenic stimulus. Subjects and Method: This is a randomized, double-blind, controlled and crossover clinical trial, involving the inclusion of 14 healthy male subjects, with complete secondary education, aged between 18 and 40. years. Participants will be randomized to receive Transcranial Direct Current Stimulation (tDCS), (2) Transcranial Alternating Current Stimulation (tACs), (3) Random Noise Current, (4) Simulated Stimulation Session and (5) Rest Session. Experimental conditions will take place in a standard, quiet and bright room. Assessments will include Motor Evoked Potential, Heat Pain Threshold, Motor Area Activation through metabolic activation measured by fNIRS and analysis of EEG frequency waves. After the baseline assessment, participants will undergo a session of transcranial stimulation, followed by an algogenic stimulus with water at zero degrees, immersion of the dominant hand for 1 minute, with rest intervals of 3 minutes between each of the four serial stimuli. After this stimulus session, outcome measurements will be carried out. Expected results: This clinical trial is expected to provide insights into how tDCS, tACs and random stimulation in to an algogenic stimulus. The results may contribute to the development of therapeutic or neuromodulation strategies in clinical conditions where the regulation of the cortico-spinal sensorimotor pathway is relevant.

02

Conditions studied

  • Health Adult Subjects

Keywords

  • tDCS
  • tACS
  • RNS
  • QST
  • CPM-test
03

In context

Lead sponsor

Hospital de Clinicas de Porto Alegre is the lead sponsor of 456 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects aged 18-45 years, with at least a high school diploma, and not engaged in night-shift work.

Exclusion criteria

Exclusion Criteria:

  • to transcranial stimulation include implanted medical devices in the brain, cardiac pacemakers, and cochlear implants.
  • Current use of psychotropic medications.
  • History of alcohol or substance abuse within the past 6 months.
  • Neurological disorders, history of traumatic brain injury, or prior neurosurgery.
  • Beck Depression Inventory-II (BDI-II) score >13.
  • Self-Reporting Questionnaire (SRQ) score >7.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
14 participants (estimated)

Study arms

  • Active comparator
    Transcranial Direct Current Stimulation (tDCS) over motor area (M1)

    Participants receive active transcranial direct current stimulation over the primary motor cortex (M1) during the intervention sessions.

    Device: Transcranial Direct Current Stimulation

  • Active comparator
    Transcranial Alternating Current Stimulation (tACS) over M1

    Participants receive active transcranial alternating current stimulation over the primary motor cortex (M1) during the intervention sessions.

    Device: Transcranial Alternating Current Stimulation

  • Active comparator
    Transcranial Random Noise Stimulation (tRNS) over M1

    Participants receive active transcranial random noise stimulation over the primary motor cortex (M1) during the intervention sessions.

    Device: Transcranial Random Noise Stimulation (tRNS)

  • Sham comparator
    Sham Stimulation

    Participants undergo sham stimulation, experiencing the same setup as active stimulation without actual current delivery.

    Device: Sham Stimulation

  • No intervention
    Rest State

    Participants remain seated with their eyes open for 20 minutes during the rest session, without performing any other task.

Interventions

  • DeviceTranscranial Alternating Current Stimulation

    Single session of active gamma transcranial alternating current stimulation delivered for 30 minutes using a battery-powered external stimulator. Stimulation is applied through two sponge electrodes (5 × 7 cm) mounted on a neoprene cap. The stimulation frequency is 40 Hz, based on previous gamma-band transcranial alternating current stimulation (tACS) studies. The anode is positioned at C3 (left primary motor cortex, M1), and the cathode over the ipsilateral clavicular region.

    Also known as: tACS

  • DeviceTranscranial Direct Current Stimulation

    Stimulation is delivered using two sponge electrodes (5 × 7 cm) mounted on a neoprene cap. The electrodes are positioned on the scalp according to the international 10-20 system. The anode is placed at position C3 (left primary motor cortex, M1) and the cathode over the ipsilateral clavicular region. The sinusoidal current intensity per channel ranges from ±2 mA. The session duration is 20 minutes.

    Also known as: tDCS

  • DeviceTranscranial Random Noise Stimulation (tRNS)

    Stimulation is delivered using two sponge electrodes mounted on a neoprene cap. The anode is positioned at C3 (left primary motor cortex, M1), and the cathode over the ipsilateral clavicular region. A random current level is generated for each sample at a sampling rate of 1280 samples per second. The random values are normally distributed, following a bell-shaped probability density function. The noise signal contains all frequencies up to half the sampling rate (maximum 640 Hz) and has no DC offset.

    Also known as: tRNS

  • DeviceSham Stimulation

    During the sham stimulation session, the tDCS device ramps up the current to 2 mA over 30 seconds and then is immediately turned off. This procedure mimics the sensations of active stimulation without delivering therapeutic current for the remainder of the session.

    Also known as: sham

06

What researchers measure

Primary outcomes

  1. Resting-State EEG Power Spectra Across Frequency Bands (Delta, Theta, Alpha, Beta 1, Beta 2, and Gamma)

    Electroencephalography (EEG) will be used to quantify neuronal activity through quantitative EEG (qEEG) analysis. Resting-state EEG power spectra will be analyzed across delta, theta, alpha, beta, and gamma frequency bands, reflecting synchronized neuronal oscillations. EEG data will be recorded using a 20-electrode montage according to the international 10-20 system during an 8-minute resting-state paradigm with alternating eyes-open and eyes-closed conditions. Cortical source localization will be performed using standardized Low-Resolution Brain Electromagnetic Tomography (sLORETA).

    Time frame: Immediately before and immediately after the intervention.

Secondary outcomes

  1. Corticospinal Excitability

    Corticospinal excitability will be assessed using single-pulse transcranial magnetic stimulation (TMS) applied over the left primary motor cortex. Motor evoked potentials (MEPs) will be recorded from the right first dorsal interosseous muscle, and measures will include resting motor threshold (RMT) and MEP amplitude, with MEPs obtained at 130% of the motor threshold.

    Time frame: Immediately before and immediately after the intervention.

  2. Motor Cortex Functional Connectivity

    Functional connectivity of the motor cortex will be assessed using functional near-infrared spectroscopy (fNIRS) with a continuous-wave NirScout® system. Optodes will be positioned according to the international 10-10 system to cover the bilateral motor cortex. Data will be acquired during resting-state conditions and during the cold pressor task. Functional connectivity will be analyzed within predefined motor cortex regions of interest.

    Time frame: Immediately before and immediately after the intervention.

  3. Heat Pain Threshold

    Heat pain threshold will be assessed via quantitative sensory testing (QST) on the left forearm using a thermode that increases temperature from 30°C to 52°C at a rate of 1°C per second. The pain threshold is calculated as the average temperature at which pain is first reported across three trials. Higher values indicate greater pain threshold.

    Time frame: Immediately before and immediately after the intervention.

  4. Function of the Descending Pain Inhibitory System

    The function of the descending pain inhibitory system will be assessed using the Conditioned Pain Modulation Test (CPM-test). Pain intensity is rated using a verbal numerical rating scale (0 = no pain to 10 = worst possible pain) before (T0) and during (T1) cold-water immersion. The CPM effect is calculated as the difference between pain ratings at T0 and T1, with greater reductions indicating more effective pain inhibition.

    Time frame: Immediately before and immediately after the intervention.

  5. Cold Pressor Test Pain Tolerance

    Pain intensity and tolerance will be assessed using the Cold Pressor Test, in which participants immerse the non-dominant hand in ice-saturated water (\~1°C) for up to 2 minutes. Pain intensity will be continuously rated using an electronic visual analog scale, allowing calculation of peak pain, mean pain, and area under the curve (AUC) over the test duration.

    Time frame: Immediately before and immediately after the intervention.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Data will be available upon request at wcaumo@hcpa.edu.br after 6 months of publication.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07831525
Responsible party
Sponsor
First posted
Sep 21, 2026
Start date
Jul 15, 2026
Primary completion
Oct 26, 2026 (estimated)
Completion
Dec 26, 2026 (estimated)
Last update
Sep 21, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion